Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
DCTH - Delcath Systems, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$25.33
DETAILS
HIGH:
$32.00
LOW:
$17.00
MEDIAN:
$27.00
CONSENSUS:
$25.33
UPSIDE:
57.72%
Stock News
Delcath Systems Q2 Earnings Call Highlights
Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma.
Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.07 per share a year ago.
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025.
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver c.
Delcath Systems to Host Second Quarter 2026 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, August 6, 202.
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either May 2026 or June 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 17,000 s.
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care (SOC) treatment for liver-dominant metastatic breast cancer (mBC). The Phase 2 trial (DELUMA; NCT06875128) will evalua.
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath's perc.
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued
On May 22, 2026, Delcath Systems Inc (DCTH) shares fell 3.8%, bringing the current price to $11.02. The stock's performance over the last year has been disappoi
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either March 2026 or April 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 24,50.
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New York, NY. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and.
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025 HEPZATO KIT™ revenue of $23.3 million, compared to $18.0 million in the first quarter of 2025 CHE.
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective analysis by independent investigators on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT® Hepatic Delivery System was presented today at the ESMO Breast Cancer Congress 2026. Presentation details Congress: ESMO Breast Cancer Congress 2026 Dat.
Delcath Systems to Host First Quarter 2026 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 7, 2026 Time.
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (April 2026). M-PHP is also re.
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Canada. At the event, Delcath's Hepatic Delivery System for use in percutaneous hepatic perfusion will be featured in three presentations. On April 13, 2026, at 2:40 PM ET, Dr. Eric We.
Contrasting Delcath Systems (NASDAQ:DCTH) & ADB International Group (OTCMKTS:EQUR)
Delcath Systems (NASDAQ: DCTH - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Profitability This table compares Delcath Systems and
Price Targets
Delcath Systems price target raised to $32 from $30 at H.C. Wainwright
$32.00
(was $15.47)
H.C. Wainwright
Delcath Systems price target raised to $17 from $16 at BTIG
$17.00
(was $13.01)
BTIG
Delcath Systems (DCTH) PT Lowered to $27 at Clear Street
$27.00
(was $9.16)
Evercore ISI
Delcath Systems (DCTH) PT Lowered to $19 at BTIG
$19.00
(was $9.16)
Marie Thibault
·
BTIG
Delcath Systems price target lowered to $20 from $24 at Craig-Hallum
$20.00
(was $11.42)
Chase Knickerbocker
·
Craig-Hallum
Delcath Systems price target lowered to $30 from $31 at H.C. Wainwright
$30.00
(was $10.97)
H.C. Wainwright
Delcath Systems price target raised to $24 from $22 at H.C. Wainwright
$24.00
(was $13.00)
H.C. Wainwright
Delcath Systems (DCTH) PT Raised to $22 at H.C. Wainwright
$22.00
(was $7.54)
Swayampakula Ramakanth
·
H.C. Wainwright